Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.
Ribonuclease T2 (RNASET2) and gametogenetin binding protein 2 (GGNBP2) are tumor suppressor genes whose expression is downregulated in ovarian and other types of cancer. However, whether the proteins encoded by these genes are associated with drug resistance has rarely been studied. Using real-time quantitative polymerase chain reaction, in the present study we showed that RNASET2 and GGNBP2 mRNA levels were significantly lower in A2780-CBP (carboplatin-resistant) and A2780-DDP (cisplatin-resistant) ovarian cancer cells than in the parental A2780 cells and were downregulated in drug-resistant ovarian cancer tissues compared with their drug-sensitive counterparts. These findings were consistent with the expression profiles determined from microarray data retrieved from the Gene Expression Omnibus Profiles database. Accordingly, we hypothesized that the downregulation of RNASET2 and GGNBP2 is involved in the development of drug resistance in ovarian cancer. A comprehensive bioinformatics analysis of the two genes was therefore conducted, including gene/protein-gene/protein interactions, biological process annotation, pathway enrichment of co-expressed genes and microRNA-mRNA analyses. The integrated results suggested that RNASET2 and GGNBP2 contributed to drug resistance in ovarian cancer, via direct or indirect interactions with a number of microRNAs, genes and proteins involved in a wide range of biological processes and pathways. The information provided in the present study provides insight for further investigations of the drug resistance-related functions of RNASET2 and GGNBP2.
Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Fuqiang
F
Yin
Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Ling
L
Liu
Center for Translational Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Xia
X
Liu
Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Gang
G
Li
Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Li
L
Zheng
Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Danrong
D
Li
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Qi
Q
Wang
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Wei
W
Zhang
Key Laboratory for High-Incidence Tumor Prevention and Treatment, Ministry of Education, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Li
L
Li
D048868:Adaptor Proteins, Signal Transducing; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D017239:Paclitaxel / Q000627:therapeutic use; D012260:Ribonucleases / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000378:metabolism
D048868:Adaptor Proteins, Signal Transducing; C487856:GGNBP2 protein, human; D035683:MicroRNAs; D025521:Tumor Suppressor Proteins; D016190:Carboplatin; D012260:Ribonucleases; C425232:RNASET2 protein, human; D017239:Paclitaxel; D002945:Cisplatin